CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
cyclophosphamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01416974
NCT01416974Phase 1Completed
CompareCT.gov

A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

Memorial Sloan Kettering Cancer Center·interventional·Posted Aug 15, 2011·Updated Jan 11, 2019

In Brief

A Phase 1 clinical trial evaluating cyclophosphamide and modified T cells for Leukemia. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The purpose of this Phase I study is to test the safety and effect of specially prepared cells collected from the patients called "modified T cells." We want to find a safe dose of modified T cells for patients who have disease remaining after initial chemotherapy. We also want to find out what effects these T cells have on you and your leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 15, 2011
Enrollment StartAug 22, 2011
Primary CompletionJan 7, 2019
TodayJul 1, 2026
Enrollment to primary: 7.4 yearsPosted 14.9 years ago

Interventions

cyclophosphamidedrug

Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.

modified T cellsbiological

followed by consolidative therapy with the modified T cells in 3 planned cohorts.